Physician profile
Zane Anwar
NPI 1699110213
$1,763.12
in general payments reported to CMS, 2019-2025
18 companies · $778 in 2025
The $778 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $426 · 2024: $560 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,763.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $601.32 | 2023-2025 | Lumigan, Alphagan P |
| New World Medical,INC. | $231.51 | 2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Via360 |
| Thea Pharma INC. | $174.49 | 2023-2025 | Iyuzeh |
| Genentech USA, INC. | $144.77 | 2023-2025 | Vabysmo |
| Astellas Pharma US INC | $122.34 | 2023-2025 | Izervay |
| Tarsus Pharmaceuticals, INC. | $110.40 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $87.75 | 2024 | Tecnis Iol |
| Dompe US, INC. | $52.67 | 2023-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $43.90 | 2024-2025 | Miebo |
| Alcon Vision LLC | $34.43 | 2023 | Clareon |
| Sight Sciences, INC. | $30.05 | 2025 | Omni Surgical System |
| Horizon Therapeutics Plc | $24.61 | 2023 | Tepezza |
| Biotissue Holdings INC. | $21.96 | 2024 | |
| Oyster Point Pharma, INC. | $18.90 | 2023 | Tyrvaya |
| Biogen, INC. | $17.54 | 2024 | Byooviz |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $16.07 | 2023 | Syfovre |
| Rxsight INC | $15.73 | 2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Ocular Therapeutix, INC. | $14.68 | 2023 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zane Anwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.